In this episode of The Midweek Takeaway, Kevin Hornsby and Charles Archer is joined by Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), to discuss positive pre-clinical results from the company’s PTSD programme, SVN-SDN-14. Three high-performing candidates with strong, balanced SERT, DAT, and NET modulation profiles are advancing to in vivo studies — a key step toward developing a new class of medicines aimed at enhancing pro-social behaviour and improving outcomes for people living with PTSD.

This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.